Literature DB >> 17917114

TWEAK and the central nervous system.

Manuel Yepes1.   

Abstract

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily that acts on responsive cells via binding to a cell surface receptor named fibroblast growth factor-inducible 14 (Fn14). TWEAK can regulate numerous cellular responses in vitro and in vivo. Recent studies have indicated that TWEAK and Fn14 are expressed in the central nervous system (CNS), and that in response to a variety of stimuli, including cerebral ischemia, there is an increase in TWEAK and Fn14 expression in perivascular astrocytes, microglia, endothelial cells, and neurons with subsequent increase in the permeability of the blood-brain barrier (BBB) and cell death. Furthermore, there is a growing body of evidence indicating that TWEAK induces the activation of the NF-kappaB in the CNS with release of proinflammatory cytokines and matrix metalloproteinases. In addition, inhibition of TWEAK activity by either treatment with a Fn14-Fc fusion protein or neutralizing anti-TWEAK antibodies has shown therapeutic efficacy in animal models of ischemic stroke, cerebral edema, and multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917114     DOI: 10.1007/s12035-007-0024-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  95 in total

Review 1.  TWE-PRIL; a fusion protein of TWEAK and APRIL.

Authors:  Geertruida M Kolfschoten; Bérengère Pradet-Balade; Michael Hahne; Jan Paul Medema
Journal:  Biochem Pharmacol       Date:  2003-10-15       Impact factor: 5.858

2.  Development of the blood-brain barrier.

Authors:  W Risau; H Wolburg
Journal:  Trends Neurosci       Date:  1990-05       Impact factor: 13.837

3.  An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein.

Authors:  B Pradet-Balade; J P Medema; M López-Fraga; J C Lozano; G M Kolfschoten; A Picard; C Martínez-A; J A Garcia-Sanz; M Hahne
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

4.  The cerebral ischemic penumbra.

Authors:  A M Hakim
Journal:  Can J Neurol Sci       Date:  1987-11       Impact factor: 2.104

5.  Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis.

Authors:  M Yepes; M Sandkvist; M K Wong; T A Coleman; E Smith; S L Cohan; D A Lawrence
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

6.  Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury.

Authors:  Z Yu; D Zhou; A J Bruce-Keller; M S Kindy; M P Mattson
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

7.  Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes.

Authors:  Long Jin; Atsuhito Nakao; Masafumi Nakayama; Noriko Yamaguchi; Yuko Kojima; Nobuhiro Nakano; Ryoji Tsuboi; Ko Okumura; Hideo Yagita; Hideoki Ogawa
Journal:  J Invest Dermatol       Date:  2004-05       Impact factor: 8.551

Review 8.  Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets.

Authors:  G Z Feuerstein; X Wang; F C Barone
Journal:  Ann N Y Acad Sci       Date:  1997-10-15       Impact factor: 5.691

9.  Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity.

Authors:  P Rieckmann; M Albrecht; B Kitze; T Weber; H Tumani; A Broocks; W Lüer; A Helwig; S Poser
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

10.  TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules.

Authors:  Sharron A N Brown; Heather N Hanscom; Hong Vu; Shelesa A Brew; Jeffrey A Winkles
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

View more
  17 in total

Review 1.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

2.  TWEAK-Fn14 Influences Neurogenesis Status via Modulating NF-κB in Mice with Spinal Cord Injury.

Authors:  Jing Xu; Jian He; Huang He; Renjun Peng; Jian Xi
Journal:  Mol Neurobiol       Date:  2016-11-07       Impact factor: 5.590

3.  Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.

Authors:  Xiaoying Chen; Vahid Farrokhi; Pratap Singh; Mireia Fernandez Ocana; Jenil Patel; Lih-Ling Lin; Hendrik Neubert; Joanne Brodfuehrer
Journal:  MAbs       Date:  2017-11-30       Impact factor: 5.857

4.  Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura.

Authors:  T Chen; Z-P Guo; M-M Li; J-Y Li; X-Y Jiao; Y-H Zhang; H-J Liu
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

5.  Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus.

Authors:  Chao Wang; Li-Li Chen; Hai-Feng Pan; Rui-Xue Leng; Wei-Zi Qin; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2011-10-04       Impact factor: 2.980

6.  TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-кB pathway.

Authors:  Hui-Na Chen; De-Jin Wang; Man-Yi Ren; Qi-Lei Wang; Shu-Jian Sui
Journal:  Mol Biol Rep       Date:  2012-05-04       Impact factor: 2.316

7.  TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.

Authors:  Jing Wen; Jessica Doerner; Karen Weidenheim; Yumin Xia; Ariel Stock; Jennifer S Michaelson; Kuti Baruch; Aleksandra Deczkowska; Maria Gulinello; Michal Schwartz; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2015-04-22       Impact factor: 7.094

Review 8.  A further TWEAK to multiple sclerosis pathophysiology.

Authors:  Arash Nazeri; Pouria Heydarpour; Shokufeh Sadaghiani; Mohammad Ali Sahraian; Linda C Burkly; Amit Bar-Or
Journal:  Mol Neurobiol       Date:  2013-07-20       Impact factor: 5.590

Review 9.  The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.

Authors:  Jeffrey A Winkles
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

Authors:  Jing Wen; Yumin Xia; Ariel Stock; Jennifer S Michaelson; Linda C Burkly; Maria Gulinello; Chaim Putterman
Journal:  J Autoimmun       Date:  2013-04-08       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.